CIK 0001781174 · <br>Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 825125532
- Phone
- 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $38,534
- in 8 filings
Net −$38,534. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blume-Jensen Peter −$34K President and CEO sold <1% of stake
- Miller Mary −$2K Chief Legal Officer sold 1% of stake
- Devroe Eric −$1K Chief Operating Officer sold <1% of stake
- Gamelin Erick −$804 Chief Development Officer sold <1% of stake
- Peterson Katharine −$203 Chief Accounting Officer sold <1% of stake
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-22 | Miller Mary Chief Legal Officer | Sale | −513 | $1.84 | $944 | 81,202 |
| 2026-10-05 | Miller Mary Chief Legal Officer | Sale | −294 | $1.99 | $585 | 81,715 |
| 2026-08-31 | Levin Michaela Chief Business Officer | Grant or award | +30,000 | 30,000 | ||
| 2026-08-31 | Levin Michaela Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2026-08-25 | Blume-Jensen Peter President and CEO | Sale | −14,036 | $2.21 | $31K | 2,230,052 |
| 2026-08-18 | Peterson Katharine Chief Accounting Officer | Sale | −101 | $2.01 | $203 | 18,033 |
| 2026-08-18 | Miller Mary Chief Legal Officer | Sale | −185 | $2.01 | $372 | 82,009 |
| 2026-08-18 | Gamelin Erick Chief Development Officer | Sale | −400 | $2.01 | $804 | 52,592 |
| 2026-08-18 | Devroe Eric Chief Operating Officer | Sale | −604 | $2.01 | $1K | 146,349 |
| 2026-08-18 | Blume-Jensen Peter President and CEO | Sale | −1,229 | $2.01 | $2K | 2,244,088 |
| 2026-08-18 | Blume-Jensen Peter President and CEO | Sale | −484 | $2.01 | $973 | 385,859 |
| 2026-08-04 | Levy Adam D. Chief Financial Officer | Sale | −1,142 | $1.57 | $2K | 66,008 |
| 2026-07-21 | Miller Mary Chief Legal Officer | Sale | −573 | $1.76 | $1K | 82,194 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | TOMSICEK MICHAEL JOHN Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | Shacham Sharon Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | Palani Santhosh Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | Magovcevic-Liebisch Ivana Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | DiRocco Derek Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2026-06-17 | BAUM CHARLES M Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 |
Page 1 of 6 · 113 trades